Invest Securities reiterates its 'buy' opinion on bioMérieux and raises its target price from 120 to 123 euros, following an investor day (CMD) which validates its preference for the group in the in vitro diagnostics market.

"In parallel with the quarterly publication marked by a further outperformance in molecular diagnostics, the group presented attractive but unsurprising medium-term targets", judges the analyst.

While the CMD offers appreciable visibility on post-Covid prospects, Invest Securities corrects the margin dynamic by including a strong acceleration from 2026 onwards, marginally impacting its 2024-25 BNA.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.